Hoth Therapeutics Inc
Company Profile
Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Contact
1177 Avenue of the Americas
5th Floor, Suite 5066
New YorkNY10036
USAT: +1 646 756-2997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
stocks
ASX healthcare leader sees further cuts to fair value
stocks
Avoid this overpriced ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,982.00 | 25.90 | 0.29% |
| CAC 40 | 8,052.43 | 58.94 | 0.74% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,409.53 | 160.01 | 1.56% |
| HKSE | 25,979.61 | 19.71 | 0.08% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,693.28 | 1,444.89 | 2.66% |
| NZX 50 Index | 13,281.05 | 186.68 | 1.43% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,751.60 | 27.50 | 0.32% |
| SSE Composite Index | 4,125.32 | 2.19 | 0.05% |